1. Infection

Infection

Infection is a pathophysiological process that involves the invasion and colonization of a living organism (host) by disease-causing infectious agents, the reaction of host tissues to these agents and the toxins they produce, and the transmission of infectious agents to other hosts. Common infectious agents include viruses, viroids, prions, bacteria, nematodes, arthropods, and other macroparasites such as tapeworms. Hosts can fight infections using their immune system. Mammals often engage both innate and adaptive immune systems to eliminate infectious agents or inhibit their growth and transmission. When infection occurs, anti-infective drugs can suppress the infection. Several broad types of anti-infective drugs exist, depending on the type of organism targeted; they include antibacterial (antibiotic), antiviral, antifungal and antiparasitic agents.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-158193
    N-Decanoyl cyclopentylamide 540796-75-6 98%
    N-Decanoyl cyclopentylamide (C10-CPA) is a potent inhibitor of quorum sensing in Pseudomonas aeruginosa. N-Decanoyl cyclopentylamide interferes with expression of Pseudomonas aeruginosa virulence factors regulated by the las and rhl quorum-sensing systems. N-Decanoyl cyclopentylamide inhibits production of elastase, pyocyanin, and rhamnolipid and biofilm formation.
    N-Decanoyl cyclopentylamide
  • HY-158323
    HGPRT/TBrHGPRT1-IN-1 3081803-13-3 98%
    HGPRT/TBrHGPRT1-IN-1 (Compound 5) is a selective inhibitor targeting human hypoxanthine-guanine phosphoribosyltransferase (HGPRT) and Trypanosoma bruce HGPRT1 (TBrHGPRT1) (both Ki=3 nM). HGPRT/TBrHGPRT1-IN-1 ultimately results in decreased cell growth. HGPRT/TBrHGPRT1-IN-1 is primarily used in the research of infectious diseases and cancer.
    HGPRT/TBrHGPRT1-IN-1
  • HY-158364
    NMT-IN-3 3061506-36-0 98%
    NMT-IN-3 is an inhibitor of N-myristoyltransferase (NMT). The IC50 of NMT-IN-3 for Plasmodium vivax NMT is 38 mM.
    NMT-IN-3
  • HY-158419
    PB(OH)3 1854111-80-0 98%
    PB(OH)3 is an anti-HIV-1 agent that can be used in antiviral research.
    PB(OH)3
  • HY-158570
    (2E)-Eicosenoic acid 2127095-72-9 98%
    (2E)-Eicosenoic acid is an inhibitor of Mycobacterium tuberculosis protein tyrosine phosphatase A (PtpA). (2E)-Eicosenoic acid exhibits strong inhibitory activity against PtpA with an IC50 value in the low micromolar range. (2E)-Eicosenoic acid can be used for research on Mycobacterium tuberculosis infection.
    (2E)-Eicosenoic acid
  • HY-158682
    LpxC-IN-13 3033881-14-7 98%
    LpxC-IN-13 (Compound 13) is a LpxC inhibitor, with an IC50 18.06 nM. LpxC-IN-13 effectively inhibits Gram-negative bacterial infection.
    LpxC-IN-13
  • HY-158687
    SARS-CoV-2 Mpro-IN-18 98%
    SARS-CoV-2 Mpro-IN-18 (compound 84) is a potent SARS-CoV-2 Mpro inhibitor with the IC50 of 3.23 nM. SARS-CoV-2 Mpro-IN-18 can be used for study of anti-SARS-CoV-2 agent.
    SARS-CoV-2 Mpro-IN-18
  • HY-158690
    DDD00057570 338965-07-4 99.69%
    DDD00057570 is a selective M17 leucyl-aminopeptidase (LAP) inhibitor. DDD00057570 inhibits L. major and L. donovani intracellular amastigotes in vitro growth.
    DDD00057570
  • HY-158700
    DprE1-IN-10 1254782-81-4 98%
    DprE1-IN-10 (hit 2) is a Decaprenylphosphoryl-β-D-ribose-2′-epimerase (DprE1) inhibitor. DprE1-IN-10 can be used for tuberculosis research.
    DprE1-IN-10
  • HY-158751
    Jun9-72-2 2657659-42-0 98%
    Jun9-72-2 is a papain (Plpro) inhibitor of SARS-CoV-2 with an IC50 value of 0.67 μM. Jun9-72-2 has antiviral activity.
    Jun9-72-2
  • HY-158763
    MPI8 856242-63-2 98%
    MPI8 (TG0205221) is an inhibitor of the major protease of SARS-CoV-2 (MPro) with high antiviral activity. MPI8 exerts its antiviral effect by dual and selective inhibition of SARS-CoV-2 MPro and host cell cysteine protease L (cathepsin L). MPI8 can be used in clinical studies of COVID-19.
    MPI8
  • HY-158815
    SM-102 N-Oxide 2824195-50-6 98%
    SM-102 N-oxide (Lipid H N-Oxide) is an impurity of SM-102 (HY-134541).
    SM-102 N-Oxide
  • HY-158818
    DXR-IN-2 2260608-07-7 98%
    DXR-IN-2 is a 1-deoxy-D-xylulose-5-phosphate reductoisomerase (DXR) inhibitor and an antimalarial agent (IC50: 0.1062 μM for Plasmodium falciparum DXR and 0.369 μM for Plasmodium falciparum). DXR-IN-2 inhibits Plasmodium falciparum growth by suppressing the methyl erythritol phosphate (MEP) pathway via DXR.
    DXR-IN-2
  • HY-158824
    Asvasiran 870094-26-1
    Asvasiran is a siRNA that targets the respiratory syncytial virus (RSV) N gene and inhibits viral replication.
    Asvasiran
  • HY-158867
    DOSPA (hydrochlorid) 913194-16-8 98%
    DOSPA hydrochlorid is a frequently utilized cationic lipid in the generation of Lipid Nanoparticles (LNPs) for the development of mRNA vaccines, including the COVID-19 vaccine.
    DOSPA (hydrochlorid)
  • HY-158905
    MTDB-Alkyne 2923694-73-7 98%
    MTDB-Alkyne is an alkyne-containing click chemistry reagent. MTDB-Alkyne can be used to synthesize Proximity-Induced Nucleic Acid Degrader (PINAD) for the degradation of SARS-CoV-2 RNA.
    MTDB-Alkyne
  • HY-158935
    Dihydro K22 2926907-58-4 98%
    Dihydro K22 is a derivative of the antiviral agent K22 (HY-122668).
    Dihydro K22
  • HY-158977
    β-Lactamase-IN-9 98%
    β-Lactamase-IN-9 (compound 2) is a β-lactamase inhibitor that can restore the sensitivity of pathogens to β-lactam antibiotics.
    β-Lactamase-IN-9
  • HY-158980
    Antifungal agent 103 3038688-81-9 98%
    Antifungal agent 103 (compound 7y) is a potent antifungal agent. Antifungal agent 103 inhibits R. solani with an EC50 of 0.47 μg/mL.
    Antifungal agent 103
  • HY-159103
    LeuRS-IN-2 98%
    LeuRS-IN-2 (Compound 9) is a Wolbachia leucyl-tRNA synthetase (LeuRS) inhibitor in the presence of adenosine monophosphate (AMP) with an EC50 value of 6 nM, efficiently arresting the growth of pathogenic host. LeuRS-IN-2 forms adenosine-based adducts inhibiting protein synthesis, which is promising for research of new antimicrobials with disrupting microbiota.
    LeuRS-IN-2
Cat. No. Product Name / Synonyms Application Reactivity